ABILITY BIOLOGICS
DEAD

Serial Number

98657872

Owner

ABILITY BIOLOGICS INC

Attorney

Max Vern

Filing Date

Jul 19, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ABILITY BIOLOGICS Trademark

Serial Number: 98657872

ABILITY BIOLOGICS is a trademark filed by ABILITY BIOLOGICS INC on July 19, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ABILITY BIOLOGICS INC (3 trademarks)

400-3 Place Ville-Marie
Montreal, Quebec H3B2E3 , CA

Entity Type: 03

Trademark Details

Filing Date

July 19, 2024

Registration Date

Not Registered

Goods & Services

antibody products and molecules acting as immune modulators for scientific and medical purposes; colostral antibodies for medical purposes; pharmaceutical antibodies for the treatment of hereditary angioedema (HAE); pharmaceutical antibodies for the treatment of respiratory diseases and respiratory syndromes; pharmaceutical antibody preparations for auto-immune diseases; pharmaceutical antibody preparations for the prevention and treatment of auto-immune diseases; pharmaceutical antibody preparations for the treatment of cancer; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories;

antibody products and molecules for scientific and medical purposes;

antibody profiling for scientific research purposes, for discovery and development of new biotherapeutics; operation of scientific database and website regarding research in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; molecule development; clinical trials; providing temporary use of a non-downloadable software for managing information in the fields of cancer, immunology, inflammation, biologics, antibodies and molecules; Platform as a service [PaaS] for analyzing molecular and clinical data to develop antibodies against immune targets; analysis in the field of molecular biology; molecular analysis and product optimization for the purpose of pharmaceutical development;

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jul 10, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 10, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 26, 2025 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 5, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 5, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 5, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 29, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 15, 2025 NWOS
NEW APPLICATION ENTERED
Jul 19, 2024 NWAP